Massachusetts Financial Services Co. MA Sells 2,491,865 Shares of Boston Scientific Corporation $BSX

Massachusetts Financial Services Co. MA reduced its position in Boston Scientific Corporation (NYSE:BSX) by 19.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,367,293 shares of the medical equipment provider’s stock after selling 2,491,865 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.70% of Boston Scientific worth $1,012,159,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Riverwater Partners LLC grew its holdings in Boston Scientific by 3.3% during the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after acquiring an additional 98 shares during the period. Gerber Kawasaki Wealth & Investment Management grew its stake in Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after purchasing an additional 99 shares during the period. Crown Wealth Group LLC increased its holdings in Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares in the last quarter. IVC Wealth Advisors LLC lifted its stake in Boston Scientific by 4.9% in the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after buying an additional 102 shares during the period. Finally, Sound View Wealth Advisors Group LLC boosted its holdings in shares of Boston Scientific by 3.9% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after buying an additional 103 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

NYSE BSX opened at $88.13 on Friday. The company has a fifty day moving average price of $96.90 and a 200-day moving average price of $100.29. The firm has a market cap of $130.65 billion, a price-to-earnings ratio of 47.13, a PEG ratio of 1.56 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the previous year, the company earned $0.63 earnings per share. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on BSX. Needham & Company LLC reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Canaccord Genuity Group reduced their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research note on Friday, November 21st. Finally, Robert W. Baird increased their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average target price of $123.89.

Insider Activity

In other news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 93,095 shares of company stock valued at $9,305,450 over the last three months. Corporate insiders own 0.50% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.